Global Primary Cells Market

Primary Cells Market Size, Share, Growth Analysis, By Type(Hematopoietic Cells, Dermatophytes, Gastrointestinal Cells, Liver Cells), By Application(Drug Discovery and Development, Regenerative Medicine, Cancer Research, Stem Cell Research), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35H2244 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 71 | Figures: 75

Primary Cells Market News

  • In May 2023, Lonza announced that it had expanded its primary cell manufacturing capacity in Singapore. The expansion will increase the company's capacity to produce primary cells by 50%.
  • In April 2023, Thermo Fisher Scientific announced that it had acquired ATCC, a leading provider of primary cells. The acquisition will give Thermo Fisher Scientific a strong portfolio of primary cells for research and development.
  • In March 2023, STEMCELL Technologies announced that it has launched a new line of primary cells, the STEMCELL Affinity™ Primary Cell Line. The STEMCELL Affinity™ Primary Cell Line is a line of primary cells that are optimised for use in research.
  • In February 2023, Cell Applications announced that it had launched a new line of primary cells, the Cell Applications™ Primary Cell Line. The Cell Applications™ Primary Cell Line is a line of primary cells that are optimised for use in drug discovery.
  • In January 2023, PromoCell announced that it had launched a new line of primary cells, the PromoCell™ Primary Cell Line. The PromoCell™ Primary Cell Line is a line of primary cells that are optimised for use in cell therapy.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Primary Cells Market size was valued at USD 4.33 billion in 2022 and is poised to grow from USD 4.89 billion in 2023 to USD 13.11 billion by 2031, growing at a CAGR of 13.1% in the forecast period (2024-2031).

Market players engage in rigorous research and development efforts to expand their product portfolios, improve cell sourcing methods, and enhance the quality of primary cells. This focus on innovation and development of novel primary cell lines aims to cater to the diverse needs of researchers and facilitate advancements in various fields, such as cancer research, regenerative medicine, and drug discovery. 'Medtronic (US)', 'Abbott Laboratories (US)', 'Boston Scientific Corporation (US)', 'BIOTRONIK SE & Co. KG (Germany)', 'LivaNova PLC (UK)', 'MicroPort Scientific Corporation (China)', 'OSCOR Inc. (US)', 'Cook Medical (US)', 'Medico S.p.A. (Italy)', 'Shree Pacetronix Ltd. (India)', 'Vitatron Holding B.V. (Netherlands)', 'Osypka Medical GmbH (Germany)', 'Lepu Medical Technology (Beijing) Co., Ltd. (China)', 'Pacetronix Ltd. (India)', 'Sorin Group (Italy)', 'Biotronik, Inc. (US)', 'Shanghai Pacemaker Co., Ltd. (China)', 'St. Jude Medical, Inc. (US)', 'ZOLL Medical Corporation (US)', 'Berlin Heart GmbH (Germany)'

Advancements in Tissue Engineering and Regenerative Medicine have significantly progressed in recent years, driving the demand for primary cells in the development of engineered tissues and organs for transplantation purposes. This increasing focus on regenerative medicine and tissue engineering has propelled the growth of the primary cells market.

Demand for Personalised Medicine: Personalised medicine focuses on tailoring medical treatments to individual patients based on their specific genetic makeup, disease characteristics, and other factors. Primary cells play a crucial role in this approach as they provide a more accurate representation of human biology compared to cell lines or animal models. Researchers and pharmaceutical companies are increasingly using primary cells to develop personalised therapies and conduct preclinical studies. The ability to study patient-specific responses and evaluate drug efficacy and safety in a more relevant cellular context has propelled the adoption of primary cells in drug discovery and development.

North America holds a significant share in the pacemaker market due to several factors. The region has well-established healthcare infrastructure, advanced medical technologies, and a high prevalence of cardiovascular diseases. Additionally, factors such as increasing healthcare expenditure, favourable reimbursement policies, and a strong presence of major pacemaker manufacturers contribute to the dominance of North America in the market. The US, in particular, has a large patient pool, sophisticated healthcare systems, and a high adoption rate of pacemakers, further solidifying the region's dominant position.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Competent Cells Market
Buy Now GET FREE SAMPLE
Single Cell Analysis Market
Buy Now GET FREE SAMPLE
Stem Cell Market
Buy Now GET FREE SAMPLE
Cell Culture Media Market
Buy Now GET FREE SAMPLE
Cell Therapy Market
Buy Now GET FREE SAMPLE
Cell Isolation/Cell Separation Market
Buy Now GET FREE SAMPLE
Cell Expansion Market
Buy Now GET FREE SAMPLE
Automated Cell Imaging System Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Primary Cells Market

Report ID: SQMIG35H2244

$5,300
BUY NOW GET FREE SAMPLE